The Cell and Gene Therapy (CGT) market is rapidly evolving from niche, cutting-edge science to FDA approved therapies that can address previously un-treatable diseases. With a rich pipeline of CGTs at various stages of development, yet continued manufacturing, regulatory, and access challenges, the crucial question to translating these incredible medical advances to approved and available products is “How can CGTs revolutionize the commercialization model to successfully bring life-changing therapies to patients sooner?”
With deep experience supporting CGT companies across the value chain, Trinity Life Sciences brings deep strategic expertise and analytical capabilities to address commercialization questions and challenges. Over the last few years, our extensive, global commercialization expertise and deep disease area experience has enabled us to support the launches of some of the most impactful cell and gene therapies. We continue to help our clients navigate unique commercialization challenges faced by this class of specialized treatments.
Webinars
Gene Therapy Uptake: The Elephant in the Room
Available On Demand
How can companies maximize their potential when launching a gene therapy product? Gene therapy commercialization is in its infancy. Limited commercial precedent creates significant difficulty in modeling gene therapy revenue and uptake. The single administration nature of the products also presents a unique challenge for companies as the eligible patient population decreases over time. In […]
Watch Now
White Papers
Gene Therapy Uptake: The Elephant in the Room
Gene therapies’ single administration nature presents a unique commercial challenge for biopharmaceutical companies; unlike traditional small molecule or biologic therapies that can be dosed chronically or repeatedly on an “as needed” basis, the one-time per patient administration of a gene therapy means that as time passes, the eligible population decreases in size. In this white […]
Read More
Webinars
Valuing an Early-Stage Asset in Pharma and Biotech: Innovative Approaches for Novel Therapies
Available On Demand
Secure success in bringing your novel therapies to market with Trinity’s innovative, holistic approach to valuing early-stage assets. Biopharma companies have been experiencing record levels of growth in recent years through M&A, co-developments, joint ventures, licensing agreements and other partnership deals. It is unlikely that this accelerated growth would have been sustained using traditional methodologies […]
Watch Now
Executive Director,
Cell & Gene Therapy
Partner
Partner &
Head of Launch Excellence
Senior Partner,
Head of Advisory and Evidence, Value, Access and Pricing (EVAP)
If you have any questions, we’re here to answer them.
We look forward to helping identify solutions for you.
